- Home
- CWST vs NUVL Comparison
CWST vs NUVL Comparison
Compare CWST & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWST
- NUVL
- Stock Information
- Founded
- CWST 1975
- NUVL 2017
- Country
- CWST United States
- NUVL United States
- Employees
- CWST N/A
- NUVL N/A
- Industry
- CWST Environmental Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- CWST Utilities
- NUVL Health Care
- Exchange
- CWST Nasdaq
- NUVL Nasdaq
- Market Cap
- CWST 6.2B
- NUVL 5.5B
- IPO Year
- CWST 1997
- NUVL 2021
- Fundamental
- Price
- CWST $113.99
- NUVL $79.49
- Analyst Decision
- CWST Buy
- NUVL Strong Buy
- Analyst Count
- CWST 6
- NUVL 11
- Target Price
- CWST $114.20
- NUVL $112.36
- AVG Volume (30 Days)
- CWST 354.8K
- NUVL 420.4K
- Earning Date
- CWST 02-12-2025
- NUVL 03-04-2025
- Dividend Yield
- CWST N/A
- NUVL N/A
- EPS Growth
- CWST N/A
- NUVL N/A
- EPS
- CWST 0.23
- NUVL N/A
- Revenue
- CWST $1,557,283,000.00
- NUVL N/A
- Revenue This Year
- CWST $15.78
- NUVL N/A
- Revenue Next Year
- CWST $6.38
- NUVL N/A
- P/E Ratio
- CWST $533.56
- NUVL N/A
- Revenue Growth
- CWST 23.15
- NUVL N/A
- 52 Week Low
- CWST $86.41
- NUVL $61.80
- 52 Week High
- CWST $116.31
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- CWST 61.63
- NUVL 43.83
- Support Level
- CWST $103.56
- NUVL $77.84
- Resistance Level
- CWST $108.93
- NUVL $85.21
- Average True Range (ATR)
- CWST 2.70
- NUVL 3.78
- MACD
- CWST 0.81
- NUVL -0.46
- Stochastic Oscillator
- CWST 81.80
- NUVL 12.08
About CWST Casella Waste Systems Inc.
Casella Waste Systems Inc is a solid waste removal company, providing resource management services to residential, commercial, municipal, and industrial customers. The company's reportable segments on Geographical basis include Eastern, Western and Mid-Atlantic regions through the Resource solution segment. It generates maximum revenue from the Western region segment. The company services include Recycling, Collection, Organics, Energy, Landfills, Special Waste as well as Professional Services.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.